

# Metropolis Healthcare Launches High-performance High-Risk HPV DNA Testing to Accelerate Cervical Cancer Screening Across India

Category: Business

written by International Khabar | February 6, 2025



- Offers Self-Sampling HPV DNA Test by Roche for early detection
- Metropolis achieves 100% concordance in verification of Self-Sampling HPV DNA test, aligning with WHO Recommendations

Ameera Shah-led **Metropolis Healthcare Limited**, India's second-largest and most respected pathology laboratory chain, today announced its collaboration with Roche Diagnostics India and Neighbouring Markets to introduce the self-sampling human papillomavirus (HPV) DNA test for cervical cancer screening. The launch of this test aims to expand access to cervical cancer screening across [India by addressing social and economic](#) barriers, making early detection more convenient for women, including those in Tier 2, Tier 3, and Tier 4 towns.



### Leadership team of Metropolis [Healthcare](#) and Roche Diagnostics

Cervical cancer is preventable and yet, India contributes to 21% of the [world's](#) total cases of cervical cancer<sup>1</sup>. Currently, it accounts for nearly 79,000 deaths among [Indian women](#) each year, which is roughly two thirds of diagnosed cases<sup>2</sup>. This indicates late-stage intervention which can be avoided by taking [precautionary measures](#) such as early screening.

The HPV DNA test, recognized by the World [Health](#) Organization (WHO) as a first-choice screening method for cervical cancer prevention<sup>3</sup>, can help bridge the gap. This cutting-edge test detects 14 high-risk HPV types in a single tube and is a clinically validated, FDA-approved, and WHO-prequalified solution. It ensures reliable and accurate diagnosis, [paving the way](#) for early intervention and better outcomes. The self-sampling HPV DNA test empowers women to take control of their [health](#) by enabling them to self-collect their samples for testing comfortably and easily. It addresses significant barriers such as stigma, discomfort, and [limited access to healthcare](#) facilities.

Commenting on the launch, **Mr. Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare Limited**, said, "Cervical [cancer remains a major health](#) challenge for Indian women, despite being preventable through early screening and vaccination. By introducing advanced screening tools like the HPV DNA test, in collaboration with Roche Diagnostics [India](#), we aim to expand access to early detection across the country. At Metropolis, we are committed to leveraging our robust scientific expertise, extensive laboratory network, and strong [partnerships with hospitals and healthcare providers to ensure](#) widespread access to this essential test. Together, we are [working toward a future](#) where cervical cancer is no longer a threat.

Considering that as per a 2020 NHFS survey, only about 1.9% women in India are currently being screened, it is clear that more needs to be done to make cervical [cancer screening accessible across India](#). Our cobas HPV DNA test provides [women with a solution](#) that allows them to overcome the potential embarrassment and discomfort that some may feel about undergoing cervical cancer screening process. I am confident that Metropolis [Healthcare's vast and established laboratory footprint will allow India](#) to adopt cervical cancer screening at a large scale, especially in underserved areas," said **Mr.**



**Rishubh Gupta, Managing Director, Roche Diagnostics India and Neighbouring Markets.**

**Dr. Kirti Chadha, Chief Scientific and Innovation Officer and Senior Oncopathologist, Metropolis Healthcare Limited,** said, *"Cervical cancer's slow progression [offers a critical window](#) for early detection, yet lack of awareness and timely screening remain significant barriers. The introduction of self-sampling high-risk HPV DNA testing is a major [step forward](#), making screening more accessible and patient-friendly. At Metropolis, we believe that every scientific solution, regardless of its potential, must be validated for performance before being introduced into a live testing [environment](#). We have successfully compared this platform with existing gold-standard [technology](#) and achieved good results with the self-sampling strategy, which is in line with WHO recommendations, advancing the potential for improved cervical cancer prevention.*

#### **About [Metropolis Healthcare Limited](#)**

Established in 1981, Metropolis Healthcare [Limited is India's](#) second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah, Promoter and Executive Chairperson. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, [healthcare providers](#), and corporates across India and Africa. The company's extensive footprint spans 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,300 [service](#) centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better [clinical outcomes](#).

Metropolis offers a comprehensive range of more than 4,000 tests and profiles, including [advanced tests for diagnosing cancer](#), neurological disorders, infectious diseases, and various genetic abnormalities. The company's commitment to

quality and accuracy is reinforced by its consistent CAP proficiency score of over 98% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of [technological](#) superiority, a warm, patient-centric approach, and reliable diagnostic reports.

For more information, please visit [www.metropolisindia.com](http://www.metropolisindia.com) or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

## References:

1. [www.ncbi.nlm.nih.gov/pmc/articles/PMC10291770/](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291770/)
2. [gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf](http://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf)
3. [WHO recommends DNA testing as a first-choice screening method for cervical cancer prevention](#)
4. [Cervical Cancer: Formulation and Implementation of Govt of India Guidelines for Screening and Management – PMC](#)

